Generic Drug News and Research RSS Feed - Generic Drug News and Research

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.
New national survey finds lack of COPD knowledge among patients

New national survey finds lack of COPD knowledge among patients

In a new national survey of chronic obstructive pulmonary disease (COPD) patients, Health Union reveals a surprising lack of awareness of risk factors and knowledge of diagnosis stage among patients. Results demonstrate a severe impact on quality of life, employment, and ability to afford treatment. [More]
Mylan announces launch of generic Namenda Tablets in U.S.

Mylan announces launch of generic Namenda Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, which is the generic version of Forest's Namenda Tablets. [More]

ANI acquires 22 previously marketed generic drug products for $25 million from Teva Pharmaceuticals

ANI Pharmaceuticals, Inc. today announced that it has acquired 22 previously marketed generic drug products from Teva Pharmaceuticals for $25 million in cash and a percentage of future gross profits from product sales. The acquisition includes 19 solid-oral dosage products, and 3 oral suspension products. [More]

CVS Health signs definitive agreement to acquire Target's pharmacy and clinic businesses for $1.9 billion

CVS Health Corporation and Target Corporation announced today that they have entered into a definitive agreement for CVS Health to acquire Target's pharmacy and clinic businesses for approximately $1.9 billion. Through this agreement, CVS Health will acquire Target's more than 1,660 pharmacies across 47 states and operate them through a store-within-a-store format, branded as CVS/pharmacy. [More]
China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2014. [More]
Study explains why generic insulin remains out of reach for diabetes patients

Study explains why generic insulin remains out of reach for diabetes patients

A generic version of insulin, the lifesaving diabetes drug used by 6 million people in the United States, has never been available in this country because drug companies have made incremental improvements that kept insulin under patent from 1923 to 2014. [More]
Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

A new study by researchers at Brigham and Women's Hospital has found that for young, healthy women taking spironolactone to treat hormonal acne, frequent office visits and blood draws are an unnecessary health care expense. [More]
Potential solutions to help reduce high cost of cancer drugs in the U.S.

Potential solutions to help reduce high cost of cancer drugs in the U.S.

Increasingly high prices for cancer drugs are affecting patient care in the U.S. and the American health care system overall, say the authors of a special article published online in the journal Mayo Clinic Proceedings. [More]
ANI acquires approved ANDA for Flecainide Acetate tablets USP

ANI acquires approved ANDA for Flecainide Acetate tablets USP

ANI Pharmaceuticals, Inc. today announced that it has acquired the approved abbreviated new drug application ("ANDA") for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals. [More]

Using MDRS to accelerate deformulation: a new whitepaper from Malvern Instruments

A new whitepaper from Malvern Instruments on Oral Solid Dose (OSD) deformulation demonstrates how the analytical technique of Morphologically Directed Raman Spectroscopy (MDRS) can be used to accelerate the development of generic products to a successful conclusion. [More]
Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan Inc. today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT. [More]
CVS Health's net revenues increase 9.7% to $35.0B in third quarter 2014

CVS Health's net revenues increase 9.7% to $35.0B in third quarter 2014

CVS Health Corporation today announced operating results for the three months ended September 30, 2014. [More]
Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

New research from CVS Health finds starting a new diabetes patient on metformin, a generic oral diabetes medicine that helps control blood sugar levels, reduced the need to add on additional treatments to control the condition over time. Although there are many classes of oral diabetes medications, there has historically been little evidence available on the comparative effectiveness of treatments to help patients and providers select an initial diabetes therapy. [More]
MPI Research announces acquisition of Jasper Clinical Research & Development

MPI Research announces acquisition of Jasper Clinical Research & Development

MPI Research today announced it has acquired the assets of Kalamazoo, Mich.-based Jasper Clinical Research & Development, Inc. Jasper is a respected clinical research organization that provides early-stage human clinical testing of promising new drugs, and is well known to pharmaceutical and biotechnology companies worldwide. [More]
Stiff rise in generic drug prices prompts probe by members of Congress

Stiff rise in generic drug prices prompts probe by members of Congress

The prices have increased by more than 1,000 percent for some of the drugs. In other news about treatments, a study finds robotic surgery may not improve care for ovarian problems and the National Cancer Institute laments that insurers' concerns about cost are keeping some patients from proton therapy trials. [More]
Doctors, hospitals went digital, but still can't share records

Doctors, hospitals went digital, but still can't share records

After spending billions to switch from paper to digital records -- much of it taxpayer subsidized through the economic stimulus package -- providers say the systems often do not share information with competitors. [More]

Drugmakers boost generic drug prices

A big increase in generic drug prices is forcing some patients to go without, reports CBS Boston. Meanwhile, U.S. News & World Report teases out some of the reasons for the slowdown in health care costs. [More]
IGI Laboratories acquires regulatory rights for 18 drug products from AstraZeneca

IGI Laboratories acquires regulatory rights for 18 drug products from AstraZeneca

IGI Laboratories, Inc., a New Jersey based specialty generic pharmaceutical company, today announced it has acquired the regulatory rights and related documents and records for 18 drug products from AstraZeneca, 17 of which were marketed. [More]

Demand for $84,000 hepatitis C drug slows

Health care providers may be waiting for other, soon-to-be-released drugs to treat hepatitis C. Also, an Indian pharmaceutical company faces Justice Department questions on pricing data for Medicaid. [More]
Gilead to boost price of new hepatitis c drug

Gilead to boost price of new hepatitis c drug

Gilead Sciences says its next generation drug to combat hepatitis C, slated to launch next month, will be more expensive than $1,000-a-pill Sovaldi, in part because the new treatment will be shorter and simpler. Gilead also struck a deal with Indian generic drugmakers to sell lower-cost versions of Sovaldi in poor countries. [More]
Advertisement
Advertisement